AVAn-Sofie Viskens

An-Sofie Viskens

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


An-Sofie Viskens has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Towards better chronic rhinosinusitis care by investigating novel therapeutic approaches that modulate the mucosal epithelial barrier

    by An-Sofie Viskens

    Chronic rhinosinusitis (CRS) is a prevalent and debilitating inflammatory condition of the nasal and paranasal sinuses, with multifactorial and often ill-defined pathophysiology, leading to major quality-of-life impairments. Current therapies largely aim at symptom control rather than remission or cure, leaving many patients with uncontrolled disease. This doctoral thesis sought to improve CRS care by identifying 1) characterizing the reasons for uncontrolled disease, 2) evaluating the real-world efficacy of two therapeutic molecules omalizumab and mepolizumab for CRSwNP, 3) examining epithelial and immunological responses to dupilumab to explore the disease-modifying effect and 4) investigating the effects of an INCS molecule on Covid-related immune effects on the epithelial barrier. We highlighted the impact of epithelial barrier dysfunction in uncontrolled disease, hence supporting the need to consider disease-modifying treatments in the future. We confirmed the effects of biologicals and showed barrier restoring and potential disease-modifying effects of dupilumab. Furthermore, we showed a potential role for the restoration of the nasal epithelial barrier as a preventive strategy against viral infections.

  • Top Cited Papers
    Open Access

    EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care

    by Peter W. Hellings, Isam Alobid, Wilma T. Anselmo‐Lima, Manuel Bernal‐Sprekelsen, Leif Bjermer, Lisa Caulley, Adam Chaker, Jannis Constantinidis, Diego M. Conti, Eugenio De Corso, et al.

    Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.


  • Open Access

    EUFOREA/EPOS2020 Statement on the Clinical Considerations for CRSwNP Care

    by Wytske Fokkens, Peter Hellings, Isam Alobid, Wilma Anselmo-Lima, Manuel Bernal-Sprekelsen, Leif Bjermer, Lisa Caulley, Adam Chaker, Jiannis Constantinidis, Diego M. Conti, et al.

    Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals, and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment, and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications, and considerations that are of importance to the patient, the physician, and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP.